Viking Therapeutics Inc (VKTX)

[XenaLives]

VK5211 Selective Androgen Receptor Modulator
Hip Fracture
Pills

Overview & Profile
Our lead clinical program is VK5211, a novel, orally available, non-steroidal selective androgen receptor modulator, or SARM, in Phase 2 development for the treatment of patients recovering from non-elective hip fracture surgery. VK5211 belongs to a family of novel non-steroidal SARM compounds based on tissue-specific gene expression and other functional, cell-based technologies. We expect VK5211 to produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to a tissue-selective mechanism of action and an oral route of administration.


Goals of SARM Therapy
-Improve Lean Body Mass (LBM)
-Improve Muscle Strength
-Improve Bone Strength
-Improve Physical Performance
-Enhance Quality of Life (QOL)

https://www.vikingtherapeutics.com/pipeline/musculoskeletal-program/